Potassium%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCl) is an electrolyte supplement used to treat or prevent hypokalemia. It is available in various formulations including oral tablets, capsules, solutions, and intravenous preparations. ## Primary Indications * Treatment of hypokalemia. * Prevention of hypokalemia, especially in patients taking diuretics that cause potassium loss. ## Adult Dosing * **Treatment of Hypokalemia:** * Oral: Typically 20-60 mEq per day in divided doses. May be increased cautiously based on serum potassium levels and clinical response. Maximum oral dose is generally 100 mEq per day. * Intravenous: 10-20 mEq per hour, not to exceed 40 mEq per hour for rapid correction in life-threatening hypokalemia. Maximum daily dose is typically 200 mEq. Higher doses may be required in severe cases but require close monitoring in an intensive care setting. * **Prevention of Hypokalemia:** * Oral: 20 mEq per day. Dosing should be guided by serum potassium levels and electrocardiogram (ECG) findings. ## Pediatric Dosing * **Treatment of Hypokalemia:** * Oral: 1-2 mEq/kg per day in divided doses, not to exceed the adult maximum of 100 mEq per day. * Intravenous: 0.5-1 mEq/kg per dose, not to exceed 20 mEq per dose, infused at a rate not exceeding 0.5 mEq/kg/hour (or 10 mEq/hour, whichever is less). Higher infusion rates may be used in emergent situations with continuous cardiac monitoring and slow infusion over 1-2 hours. Maximum daily dose typically 100-200 mEq. Dosing must be individualized based on severity of hypokalemia, serum potassium, and clinical status. ## Dose Adjustments * Renal Impairment: Use with extreme caution. Reduced doses may be necessary. Monitor serum potassium closely. Intravenous administration is generally contraindicated in severe renal impairment. ## Contraindications * Hyperkalemia. * Conditions causing sustained high potassium levels (e.g., untreated Addison's disease, anuria, severe burns, crush injuries, certain genetic disorders). * Known hypersensitivity to potassium chloride. * Certain gastrointestinal obstructions or delayed gastric emptying. ## Adverse Effects * **Common:** Nausea, vomiting, diarrhea, abdominal pain, flatulence. * **Serious:** Hyperkalemia (muscle weakness, fatigue, paresthesias, arrhythmias, cardiac arrest), gastrointestinal ulceration, bleeding, or perforation (especially with sustained-release oral formulations or rapid IV infusion). Esophageal or intestinal erosion can occur with oral tablets if not taken with sufficient fluid or if there is underlying GI pathology. ## Key Drug Interactions * **ACE Inhibitors, ARBs, Potassium-Sparing Diuretics (e.g., spironolactone, amiloride), NSAIDs, Heparin, Trimethoprim:** Increased risk of hyperkalemia. * **Corticosteroids:** May antagonize the effect of potassium, leading to hypokalemia. * **Digoxin:** Hypokalemia increases the risk of digoxin toxicity. Hyperkalemia reduces the therapeutic effect of digoxin. * **Diuretics (Loop and Thiazide):** Can increase potassium excretion, necessitating potassium supplementation. ## Monitoring * Serum potassium levels (frequently, especially during initiation, dose changes, or IV administration). * Renal function (serum creatinine, BUN). * ECG for signs of hyperkalemia (peaked T waves, prolonged QRS, loss of P waves). * Signs and symptoms of hypokalemia (muscle weakness, cramps, fatigue, arrhythmias) and hyperkalemia. ## Clinical Pearls * Oral potassium chloride should always be taken with sufficient water to prevent gastrointestinal irritation and potential ulceration. * Sustained-release formulations may reduce GI upset but can also increase the risk of GI obstruction or perforation in susceptible patients. * Rapid intravenous infusion of potassium chloride can cause cardiac arrest. Never administer as an undiluted bolus. * The concentration of IV potassium chloride solutions should be limited to avoid phlebitis and pain at the infusion site; concentrations higher than 40 mEq/L are generally not recommended peripherally. --- *This information is intended for healthcare professionals and does not replace the need to consult the official prescribing information and current clinical guidelines.*